Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chronic hepatitis B viral (HBV) infection remains a major health threat, especially in high-prevalence areas. Most infants infected by mother-to-infant HBV transmission become chronic carriers. In Taiwan, many important preventive interventions have been implemented to block the perinatal transmission of HBV in the past 35 years. The first nationwide universal HBV vaccination program was launched in Taiwan in July 1984. The three-dose HBV vaccine completion rate reached 98.1% in 2018. The prevalence of Hepatitis B surface antigen (HBsAg) decreased from 9.8% in pre-vaccinated period in 1984 to 0.5% in the vaccinated cohort in 2014. The incidence of hepatocellular carcinoma in children aged 6–9 years significantly declined from 0.52 to 0.13 per 100,000 children born before and after 1984, respectively. Furthermore, we have performed a maternal HBV screening program during pregnancy since 1984, with the screening rate peaked at 93% in 2012. The HBsAg- and HBeAg-seropositive rate in pregnant women declined from 13.4% and 6.4% in 1984–1985 to 5.9% and 1.0% in 2016, respectively. To closely control perinatal HBV infection, we have administered hepatitis B immunoglobulin immediately after birth and checked the serum level of HBsAg and anti-HBs in high-risk babies born to HBsAg-seropositive mothers, irrespective of their HBeAg status, since July 2019. We have also adopted short-term antiviral treatments such as tenofovir 300 mg daily in the third trimester for highly viremic mothers and reduced the perinatal infection rates from 10.7 to 1.5%. Through all these efforts, we expect to meet the global goal of eliminating HBV infection by 2030.
Abstract
Chronic hepatitis B viral (HBV) infection remains a major health threat, especially in high-prevalence areas. Most infants infected by mother-to-infant HBV transmission become chronic carriers. In Taiwan, many important preventive interventions have been implemented to block the perinatal transmission of HBV in the past 35 years. The first nationwide universal HBV vaccination program was launched in Taiwan in July 1984. The three-dose HBV vaccine completion rate reached 98.1% in 2018. The prevalence of Hepatitis B surface antigen (HBsAg) decreased from 9.8% in pre-vaccinated period in 1984 to 0.5% in the vaccinated cohort in 2014. The incidence of hepatocellular carcinoma in children aged 6–9 years significantly declined from 0.52 to 0.13 per 100,000 children born before and after 1984, respectively. Furthermore, we have performed a maternal HBV screening program during pregnancy since 1984, with the screening rate peaked at 93% in 2012. The HBsAg- and HBeAg-seropositive rate in pregnant women declined from 13.4% and 6.4% in 1984–1985 to 5.9% and 1.0% in 2016, respectively. To closely control perinatal HBV infection, we have administered hepatitis B immunoglobulin immediately after birth and checked the serum level of HBsAg and anti-HBs in high-risk babies born to HBsAg-seropositive mothers, irrespective of their HBeAg status, since July 2019. We have also adopted short-term antiviral treatments such as tenofovir 300 mg daily in the third trimester for highly viremic mothers and reduced the perinatal infection rates from 10.7 to 1.5%. Through all these efforts, we expect to meet the global goal of eliminating HBV infection by 2030.
참고문헌 (41)
- Global hepatitis report, 2017, "World Health Organization", World Health Organization, ~ (2017)
- Smith S, "Global progress on the elimination of viral hepatitis as a major public health threat : an analysis of WHO Member State responses 2017", JHEP Rep, 1, pp.81~89 (2019)
- Hutin YJ, "How far are we from viral hepatitis elimination service coverage targets?", J Int AIDS Soc, 21(Suppl 2), pp.e25050~ (2018)
- Chang MH, "Hepatitis B vaccination : disease and cancer prevention-a Taiwanese experience", Clin Liver Dis, 14, pp.521~530 (2010)
- Hsu SC, "Horizontal transmission of hepatitis B virus in children", J Pediatr Gastroenterol Nutr, 16, pp.66~69 (1993)
- Ni YH, "Hepatitis B vaccination in children: the Taiwan experience", Pathol Biol(Paris), 58, pp.296~300 (2010)
- Chien YC, "Nationwide hepatitis B vaccination program in Taiwan : effectiveness in the 20 years after it was launched", Epidemiol Rev, 28, pp.126~135 (2006)
- Nayagam S, "Strategies for global elimination of chronic HBV infection : 2019 update", Curr Hepatol Rep, 18, pp.300~309 (2019)
- Su WJ, "The impact of universal infant hepatitis B immunization on reducing the hepatitis B carrier rate in pregnant women", J Infect Dis, 220, pp.1118~1126 (2019)
- Lin CC, "Hepatitis B virus infection among pregnant women in Taiwan : comparison between women born in Taiwan and other southeast countries", BMC Public Health, 8, pp.49~ (2008)
- Chen HL, "Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV", Gastroenterology, 142, pp.773~781 (2012)
- Chen SC, "Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment", Pediatrics, 131, pp.e1135~43 (2013)
- Hsu HY, "Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984 : a study just before mass hepatitis B vaccination program in Taiwan", J Med Virol, 18, pp.301~307 (1986)
- Tsen YJ, "Seroprevalence of hepatitis B virus infection in children in Taipei, 1989 : five years after a mass hepatitis B vaccination program", J Med Virol, 34, pp.96~99 (1991)
- Chen HL, "Seroepidemiology of hepatitis B virus infection in children : ten years of mass vaccination in taiwan", JAMA, 276, pp.906~908 (1996)
- Ni YH, "Hepatitis B virus infection in children and adolescents in a hyperendemic area : 15 years after mass hepatitis B vaccination", Ann Intern Med, 135, pp.796~800 (2001)
- Ni YH, "Two decades of universal hepatitis B vaccination in taiwan : impact and implication for future strategies", Gastroenterology, 132, pp.1287~1293 (2007)
- Ni YH, "Minimization of hepatitis B infection by a 25-year universal vaccination program", J Hepatol, 57, pp.730~735 (2012)
- Ni YH, "Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan", Clin Gastroenterol Hepatol, 14, pp.1324~1330 (2016)
- World Health Organization, "Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis" (2016), World Health Organization
- Lu CY, "Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization", J Infect Dis, 197, pp.1419~1426 (2008)
- Chang MH, "Fulminant hepatitis in children in Taiwan : the important role of hepatitis B virus", J Pediatr, 111, pp.34~39 (1987)
- Kao JH, "Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan", J Pediatr, 139, pp.349~352 (2001)
- Chen HL, "Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection : 15 years after universal hepatitis B vaccination", Hepatology, 39, pp.58~63 (2004)
- Chiang CJ, "Thirty-year outcomes of the national hepatitis B immunization program in Taiwan", JAMA, 310, pp.974~976 (2013)
- Chang MH, "Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma", Cancer, 64, pp.2377~2380 (1989)
- Chang MH, "Long-term effects of hepatitis B immunization of infants in preventing liver cancer", Gastroenterology, 151, pp.472~480 (2016)
- Chang MH, "Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children", N Engl J Med, 336, pp.1855~1859 (1997)
- Chang MH, "Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees : a 20-year follow-up study", J Natl Cancer Inst, 101, pp.1348~1355 (2009)
- Wen WH, "Mother-to-infant transmission of hepatitis B virus infection : significance of maternal viral load and strategies for intervention", J Hepatol, 59, pp.24~30 (2013)
- Tang JR, "Hepatitis B surface antigenemia at birth : a long-term follow-up study", J Pediatr, 133, pp.374~377 (1998)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- Chen HL, "Management of pregnant women and children : focusing on preventing mother-to-infant transmission", J Infect Dis, 216(suppl_8), pp.S785~791 (2017)
- Song J, "Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus : a meta-analysis", J Viral Hepat, 26, pp.397~406 (2019)
- Chen HL, "Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus", Hepatology, 62, pp.375~386 (2015)
- Pan CQ, "Tenofovir to prevent hepatitis B transmission in mothers with high viral load", N Engl J Med, 374, pp.2324~2334 (2016)
- Jourdain G, "Tenofovir versus placebo to prevent perinatal transmission of hepatitis B", N Engl J Med, 378, pp.911~923 (2018)
- Wen WH, "Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection", Hepatology, 64, pp.1451~1461 (2016)
- Chang KC, "Decreased neonatal hepatitis B virus(HBV)viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers", Aliment Pharmacol Ther, 50, pp.306~316 (2019)